Urology: Clinical Research Program


Urology: Clinical Studies Open For Enrollment


ARTEMIS: Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study


  • Male or female, 18 Years to 90 Years
  • Participant weighs ≥ 30 kg
  • Planned non-emergent sternotomy with CPB procedure for the following surgeries:
    • Multi-vessel CABG
    • Valve replacement or repair; ascending aorta surgery permitted if combined with aortic valve replacement/repair
    • Combined CABG and valve surgery; inclusion of single-vessel CABG when combined with valve replacement/repair is permitted
  • Exclusion Criteria  
    • Emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the Investigator
    • Single-vessel CABG without valve surgery is planned
    • Off-pump surgery is planned (eg, surgery without CPB).
    • Recipient of a solid organ or bone marrow transplantation.
    • Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization.
    • Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT05746559

Principal Investigator

Cary Passik, MD

Contact for Study Screening